Unknown

Dataset Information

0

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.

ABSTRACT:

SUBMITTER: Mascarenhas J 

PROVIDER: S-EPMC6530779 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
| S-EPMC5665563 | biostudies-literature
Unknown Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
| S-EPMC4490373 | biostudies-literature
Unknown ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
| S-EPMC7509854 | biostudies-literature
Unknown Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
| S-EPMC5286940 | biostudies-literature
Unknown Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.
| S-EPMC4919663 | biostudies-literature
Unknown A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
| S-EPMC5292677 | biostudies-literature
Unknown Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
| S-EPMC2424161 | biostudies-literature
Unknown Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial.
| S-EPMC10092883 | biostudies-literature
Unknown Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
| S-EPMC4081385 | biostudies-literature
Unknown Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
| S-EPMC5146859 | biostudies-literature